RT journal article
T1 Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting
A1 González García, Pablo
A1 Moares Fernández, Noelia del Carmen
A1 Yi-He, Wenjie
A1 Luna-Espejo, Rosa
A1 Fernandez-Cisnal, Ricardo
A1 Ocaña-Cuesta, Javier
A1 Muñoz Miranda, Juan Pedro
A1 Gabucio López, Antonio
A1 Fernández Ponce, Cecilia Matilde
A1 García Cózar, Francisco José
A2 BiomedicinaBiotecnología y Salud Pública
K1 acute lymphoblastic leukemia (ALL)
K1 chimeric antigen receptor (CAR)
K1 immunotherapy
K1 intein
K1 modular CAR
K1 non-Hodgkin's lymphoma (NHL)
AB Development of chimeric antigen receptor T-cell therapy has revolutionized the treatment of B-cell malignancies, although challenges such as antigen escape and tumor heterogeneity often decrease treatment success. Modular CARs targeting multiple antigens have been proposed as an interesting solution to address these challenges by reducing the likelihood of tumor cells evading treatment through the loss of a single antigen. In this study, we present a new modular CAR platform, termed CARtein, which takes advantage of intein interactions to jointly target CD19 and CD20 antigens. We demonstrate that the CARtein system, which features a universal CAR signaling backbone that covalently binds to specific scFv-intein recognition partners, generates fully active CARs. Functionality was validated using Raji cells and K562 cells expressing CD19 and/or CD20, observing significant T cell activation through NFAT and NFκB promoter activity and CD69 upregulation. Overall, our study lays the foundation for the establishment of a new way to target multiple antigens through a universal and inert CAR backbone with highly specific activation. © 2025 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
SN 1878-0261
YR 2026
FD 2026
LK http://hdl.handle.net/10498/39277
UL http://hdl.handle.net/10498/39277
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 05-nov-2026